COMPASS THERAPEUTICS, INC.
Income Statement
| Line Item | Jul 2026 | Jun 2026 | Apr 2026 | Mar 2026 | Feb 2026 | Dec 2025 | Oct 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | $13.4M | — | — | — | $12.8M |
| SG&A Expense | — | $7.4M | — | $6.9M | — | — | — | $3.0M |
| Operating Income | — | $-27.0M | — | $-20.3M | — | — | — | $-15.8M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-25.2M | — | $-18.3M | — | — | — | $-14.3M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.13 | — | $-0.10 | — | — | — | $-0.08 |
| EPS (Diluted) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Basic) | 180.1M | 186.8M | 180.1M | 186.4M | 180.1M | 178.3M | 177.9M | 168.8M |
| Shares Outstanding (Diluted) | 180.1M | 186.8M | 180.1M | 186.4M | 180.1M | 178.3M | 177.9M | 168.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |